DT05 Rec'd PCT/PTO 0 7 OCT 2007

I hereby the fify that this correspondence is being deposited with the United States Postal Service on the date set forth below as First Class Mail in approach pe addressed to: Commissioner for Patents, Box Non-Fee, Washington, DC 20231.

Date of Signature and Deposit: September 30, 2002

This Don

**PATENT** 

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Richard J. Roman

Date: September 30, 2002

David R. Harder Noriyuki Miyata Masakazu Sato Kazuya Kameo Shigeru Okuyama

Serial No.:

09/937,946

**Group Art Unit:** 

Filed:

October 2, 2001

Examiner:

Title: USE OF 20-HETE SYNTHESIZING ENZYME

INHIBITORS AS THERAPY FOR CEREBRAL

VASCULAR DISEASES

Docket No.: 650053.91533

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner For Patents Box Non-Fee Washington, DC 20231

Dear Sir:

Enclosed is a completed Form PTO-1449 listing additional documents that the applicant in the above-identified application wishes to bring to the attention of the Examiner for consideration in connection with the examination on the merits of this application. The documents were cited in the International Search Report in a corresponding PCT patent application. A copy of the International Research Report is enclosed for the Examiner's perusal.

No fee is believed due in connection with this submission. However, if a fee is due, please charge the fee to Deposit Account No. 17-0055.

Respectfully submitted,

Zhibin Ren

Reg. No. 47,897

Attorney for Applicants

QUARLES & BRADY LLP

P.O. Box 2113

Madison, WI 53701-2113

TEL 608/251-5000 FAX 608/251-9166

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no page are required to respond to a collection of information unless it to be a valid OMB control number.

Substitute for form 1449A/PTO

Sheet

NFORMATION DISCLOSURE	
STATEMENT BY APPLICANT	

(use as many sheets as necessary)

of

Comp	Known
Application Number	09/937,946
Filing Date	10/02/2001
First Named Inventor	Richard J. Roman
Group Art Unit	
Examiner Name	
Attorney Docket Number	650053.91533

Examiner	Cite	or 1	Foreign Patent Document		Name of Patentee or	Date of Publication of	Pages, Columns, Lines, Where Relevant Passages	т•	
Initials*	No. 1	Office <sup>3</sup>	Number <sup>4</sup>	Kind Code⁵ (if known)	Applicant of Cited Document	Cited Document MM-DD-YYYY	or Relevant Figures Appear		
			WO9943310		ROMAN, et al.	09-02-1999	<u>'</u>		
			· · · · · · · · · · · · · · · · · · ·						
								-	
						<u> </u>	,		
				:					
			OTHER PRIOR AR	T – NON	PATENT LITERATURE	DOCUMENTS	·		
Examiner Initials*	Cite No.	1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.						
		inhib on a	pition of potassium activation of protein	n current n kinase	osatetraenoic acid-indu in cerebral vascular s C. J Biol Chem. 1997	mooth muscle is Oct 24;272(43	s dependent		
			ZOU, et al., Inhibition of renal vascular 20-HETE production impairs autoregulation of renal blood flow. Am J Physiol. 1994 Feb;266(No. 2 Pt 2):F275-82.						
					tent and selective inhib 1 Jun;133(3):325-9.	itor of 20-HETE	synthesizing		

EXAMINER SIGNATURE		DATE CONSIDERED			
*EYAMINED: Initial if reference considered whether or not sitation is in conformance with MDED 200. Draw line through sitation if not in conformance and not					

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 5 Applicant is to place a check mark here if English language Translation is attached.